Venous thromboembolitic complications in children and adults with permanent venous access (literature review)



如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Introduction. Over the past decades, permanent venous access devices, in particular port systems and peripherally implanted central catheters, has been increasingly introduced in adult and pediatric oncology. As far as central catheters and permanent access devices are foreign bodies in basic veins, quite naturally that they are one more risk factor for thrombosis.
Material and methods. The authors searched literature data ( in Russian and English) for the period up to May 3, 2022 using public databases (Embase, Medline/PubMed, Researchgate, medrxiv.org, RSCI/eLibrary). The following keywords were used for the search: “port-system”, “peripherally implanted central catheter”, “totally implanted vascular access device”, “venous thromboembolism”, “VTE”, “venous thromboembolic complications”, “VTEC”, “catheter dysfunction”, “device malfunction”. Available preprints, articles with “in press” or “online first” status, and clinical cases were also included in the analysis.
Conclusion. This review discusses prevention, diagnostics and treatment of venous thromboembolic complications in cancer patients using similar implantable devices. In patients with catheter-associated thromboses, of practical interest are various diagnostic and curative algorithms, recommendations on the choice of vascular access, medicamentous therapy as well as variants of surgical intervention.

作者简介

M. Cherkashin

Medical and Diagnostic Center of the International Institute of Biological Systems named after Sergey Berezin

编辑信件的主要联系方式.
Email: mc@ldc.ru
ORCID iD: 0000-0002-5113-9569

Mikhail А. Cherkashin, Deputy Chief Medical Officer, Surgeon

191144, St. Petersburg

俄罗斯联邦

S. Alexandrov

Medical and Diagnostic Center of the International Institute of Biological Systems named after Sergey Berezin

Email: fake@neicon.ru
ORCID iD: 0000-0002-4429-5723

191144, St. Petersburg

俄罗斯联邦

T. Bolshakova

Medical and Diagnostic Center of the International Institute of Biological Systems named after Sergey Berezin

Email: fake@neicon.ru
ORCID iD: 0000-0002-0757-4862

191144, St. Petersburg

俄罗斯联邦

A. Nikolaev

Medical and Diagnostic Center of the International Institute of Biological Systems named after Sergey Berezin

Email: fake@neicon.ru
ORCID iD: 0000-0001-7337-2495

191144, St. Petersburg

俄罗斯联邦

K. Boyko

Medical and Diagnostic Center of the International Institute of Biological Systems named after Sergey Berezin

Email: fake@neicon.ru
ORCID iD: 0000-0003-3293-0061

191144, St. Petersburg

俄罗斯联邦

N. Berezina

Medical and Diagnostic Center of the International Institute of Biological Systems named after Sergey Berezin

Email: fake@neicon.ru
ORCID iD: 0000-0001-9772-4387

191144, St. Petersburg

俄罗斯联邦

参考

  1. Marcy P., Thariat J., Lacout A. et al. Further data about catheter related venous thrombosis in oncology. Thromb Res. 2014; 134(1): 207–9. https://doi.org/10.1016/j.thromres.2014.04.003
  2. Wiegering V., Schmid S., Andres O. et al. Thrombosis as a complication of central venous access in pediatric patients with malignancies: a 5-year single-center experience. BMC Hematol. 14, 18(2014). https://doi.org/10.1186/2052-1839-14-18
  3. Broviac J.W., Cole J.J., Scribner B.H. A silicone rubber atrial catheter for prolonged parenteral alimentation. Surg Gynecol Obstet. 1973; 136(4): 602–6.
  4. Hickman R.O., Buckner C.D., Clift R.A., et al. A modified right atrial catheter for access to the venous system in marrow transplant recipients. Surg Gynecol Obstet. 1979; 148(6): 871–5.
  5. Hoshal V.L. Jr. Total intravenous nutrition with peripherally inserted silicone elastomer central venous catheters. Arch Surg. 1975; 110(5): 644–6. https://doi.org/10.1001/archsurg.1975.01360110190032
  6. Belin R.P., Koster J.K. Jr, Bryant L.J., Griffen W.O. Jr. Implantable subcutaneous feeding chamber for noncontinuous central venous alimentation. Surg Gynecol Obstet. 1972; 134(3): 491–3.
  7. Niederhuber J.E., Ensminger W., Gyves J.W., et al. Totally implanted venous and arterial access system to replace external catheters in cancer treatment. Surgery. 1982; 92(4): 706–12.
  8. Jiang M., Li C.L., Pan C.Q., et al. Risk of venous thromboembolism associated with totally implantable venous access ports in cancer patients: A systematic review and meta-analysis. J Thromb Haemost. 2020; 18(9): 2253–73. https://doi.org/10.1111/jth.14930
  9. Raffini L., Trimarchi T., Beliveau J., Davis D. Thromboprophylaxis in apediatric hospital: a patient-safety and quality-improvement initiative. Pediatrics. 2011; 127: e1326–32. https://doi.org/10.1542/peds.2010-3282
  10. Higgerson R.A., Lawson K.A., Christie L.M., et al. Incidence and risk factors associated with venous thrombotic events in pediatric intensive care unit patients. Pediatr Crit Care Med. 2011; 12: 628–34. https://doi.org/10.1097/PCC.0b013e318207124a
  11. Ashrani A.A., Gullerud R.E., Petterson T.M. et al. Risk factors for incident venous thromboembolism in active cancer patients: a population based case–control study. Thromb Res. 2016; 139: 29–37. https://doi.org/10.1016/j.thromres.2016.01.002
  12. Verso M., Agnelli G.J. Venous thromboembolism associated with longterm use of central venous catheters in cancer patients. J Clin Oncol. 2003; 21: 3665–75. https://doi.org/10.1200/JCO.2003.08.008
  13. Эрлих А.Д., Атаканова А.Н., Неешпапа А.Г., Черепанова Н.А., Барбараш О.Л., Муллова И.С., Бернс С.А., Шмидт Е.А., Дупляков Д.В. Российский регистр острой тромбоэмболии лёгочной артерии СИРЕНА: характеристика пациентов и лечение в стационаре. Российский кардиологический журнал. 2020; 25(10): 3849. https://doi.org/10.15829/1560-4071-2020-3849
  14. Эрлих А.Д., Барбараш О.Л., Бернс С.А. и др. Тромбоэмболия лёгочных артерий у пациентов с онкологическими заболеваниями. Данные регистра СИРЕНА. Флебология. 2021; 15(3):179–86. https://doi.org/10.17116/flebo202115031179
  15. Marin A., Bull L., Kinzie M., et al Central catheter-associated deep vein thrombosis in cancer: clinical course, prophylaxis, treatment. BMJ Supportive & Palliative Care. 2021; 11: 371–80. https://doi.org/10.1136/bmjspcare-2019-002106
  16. Van Rooden C.J., Rosendaal F.R., Barge R.M.Y., et al. Central venous catheter related thrombosis in haematology patients and prediction of risk by screening with Doppler-ultrasound. Br J Haematol. 2003; 123: 507–12. https://doi.org/10.1046/j.1365-2141.2003.04638.x
  17. Piran S., Ngo V., Mc Diarmid S., et al. Incidence and risk factors of symptomatic venous thromboembolism related to implanted ports in cancer patients. Thromb Res. 2014; 133(1): 30–3. https://doi.org/10.1016/j.thromres.2013.10.026
  18. Черкашин М.А., Серов А.В., Березина Н.А. и др. Венозные тромбоэмболические осложнения у пациентов, получающих химиотерапию через порт-системы постоянного венозного доступа. Флебология. 2016; 10(4): 176–81. https://doi.org/10.17116/flebo2016104176-181
  19. Fang S., Yang J., Song L. et al. Comparison of three types of central venous catheters in patients with malignant tumor receiving chemotherapy. Patient Prefer Adherence. 2017; 11: 1197–204. https://doi.org/10.2147/PPA.S142556
  20. Chopra V., Anand S., Hickner A., et al. Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis. Lancet. 2013; 382(9889): 311–25. https://doi.org/10.1016/S0140-6736(13)60592-9
  21. Wang P., Soh K.L., Ying Y. et al. Risk of VTE associated with PORTs and PICCs in cancer patients: A systematic review and meta-analysis. Thromb Res. 2022; 213: 34–42. https://doi.org/10.1016/j.thromres.2022.02.024
  22. Бицадзе В.О., Бредихин Р.А., Булатов В.Л. и др. Флебит и тромбофлебит поверхностных сосудов. Флебология. 2021; 15(3): 211–44. https://doi.org/10.17116/flebo202115031211
  23. Wall C., Moore J., Thachil J. Catheter-related thrombosis: A practical approach. J Intensive Care Soc. 2016; 17(2): 160–7. https://doi.org/10.1177/1751143715618683
  24. Rajasekhar A, Streiff MB. How I treat central venous access devicerelated upper extremity deep vein thrombosis. Blood. 2017; 129(20): 2727–36. https://doi.org/10.1182/blood-2016-08-693671
  25. Baskin J.L., Pui C.H., Reiss U., et al. Management of occlusion and thrombosis associated with long-term indwelling central venous catheters. Lancet. 2009; 374(9684): 159–69. https://doi.org/10.1016/S0140-6736(09)60220-8
  26. Citla Sridhar D, Abou-Ismail MY, Ahuja SP. Central venous catheter-related thrombosis in children and adults. Thromb Res. 2020; 187: 103–12. https://doi.org/10.1016/j.thromres.2020.01.017
  27. Di Nisio M., Van Sluis G.L., Bossuyt P.M., et al. Accuracy of diagnostic tests for clinically suspected upper extremity deep vein thrombosis: a systematic review. J Thromb Haemost. 2010; 8(4): 684–92. https://doi.org/10.1111/j.1538-7836.2010.03771.x
  28. Murray J., Precious E., Alikhan R. Catheter-related thrombosis in cancer patients. Br J Haematol. 2013; 162(6): 748–57. https://doi.org/10.1111/bjh.12474
  29. Linenberger M.L. Catheter-related thrombosis: risks, diagnosis, and management. J Natl ComprCancNetw. 2006; 4(9): 889–901. https://doi.org/10.6004/jnccn.2006.0074
  30. Machat S., Eisenhuber E., Pfarl G., et al. Complications of central venous port systems: a pictorial review. Insights Imaging. 2019; 10(1): 86. https://doi.org/10.1186/s13244-019-0770-2
  31. Debourdeau P., Farge D., Beckers M., et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost. 2013; 11(1): 71–80. https://doi.org/10.1111/jth.12071
  32. Daeihagh P., Jordan J., Chen G.J, Rocco M. Efficacy of tissue plasminogen activator administration on patency of hemodialysis access catheters. American Journal of Kidney Diseases. 2000; 36(1): 75–9. https://doi.org/10.1053/ajkd.2000.8273
  33. Muller C., Jacquier A., Varoquaux A., et al. Utilisation de l’urokinase dans le traitement des occlusions de PICC-lines [Urokinase in the management of occluded PICC lines]. J Radiol. 2010; 91(3,Part1): 287–91. https://doi.org/10.1016/s0221-0363(10)70040-8 (In French)
  34. Muguet S., Couraud S., Perrot E., et al. Clearing obstructed totally implantable central venous access ports: an efficient protocol using a second needle. Support Care Cancer . 2012; 20(11): 2859–64. https://doi.org/10.1007/s00520-012-1412-0
  35. Schindler J., Bona R.D., Chen H.H., et al. Regional thrombolysis with urokinase for central venous catheter-related thrombosis in patients undergoing high-dose chemotherapy with autologous blood stem cell rescue. Clin Appl Thromb Hemost. 1999; 5(1): 25–9. https://doi.org/10.1177/107602969900500106
  36. Abel L., Uhde B., Dembinski R., Schraepler K. Management einer portassoziierten Vena-cava-superior-Thrombose im Rahmen eines Crohn-Schubes [Management of a Port Catheter-Related Superior Vena Cava Thrombosis in the Setting ofActiveCrohn's Disease: A Case Report]. Dtsch Med Wochenschr. 2017; 142(15): 1155–7. https://doi.org/10.1055/s-0043-112231 (In German)
  37. Bishop L., Dougherty L., Bodenham A., et al. Guidelines on the insertion and management of central venous access devices in adults. Int J Lab Hematol. 2007; 29(4): 261–78. https://doi.org/10.1111/j.1751-553X.2007.00931.x
  38. Watson H.G., Keeling D.M., Laffan M., et al. British Committee for Standards in Haematology. Guideline on aspects of cancer-related venous thrombosis. Br J Haematol. 2015; 170(5): 640–8. https://doi.org/10.1111/bjh.13556
  39. Fischer L., Knebel P., Schröder S., et al. Reasons for explantation of totally implantable access ports: a multivariate analysis of 385 consecutive patients. Ann Surg Oncol. 2008; 15(4): 1124–9. https://doi.org/10.1245/s10434-007-9783-z
  40. Zerati A.E., Wolosker N., de Luccia N., Puech-Leão P. Cateteres venosos totalmente implantáveis: histórico, técnica de implante e complicações [Fully implantable venous catheters: history, implantation technique and complications]. J Vasc Bras. 2017; 16(2): 128–39. https://doi.org/10.1590/1677-5449.008216 (In Portuguese)
  41. Nishinari K., Wolosker N., Bernardi C.V., Yazbek G. Totally-implantable ports connected to valved catheters for chemotherapy: experience from 350 Groshong devices. J Vasc Access. 2010; 11(1): 17–22.
  42. Amberger H., Baumgartner I/, Kucher N., Schindewolf M. Endovascular port-a-cath rescue in acute thrombotic superior vena cava syndrome. J Vasc Surg Cases Innov Tech. 2019; 5(2): 169–73. https://doi.org/10.1016/j.jvscit.2019.03.005
  43. Volpi S., Doenz F., Qanadli S.D. Superior Vena Cava (SVC) Endovascular Reconstruction with Implanted Central Venous Catheter Repositioning for Treatment of Malignant SVC Obstruction. Front Surg. 2018; 5: 4. https://doi.org/10.3389/fsurg.2018.00004
  44. Kostopoulou V., Tsiatas M.L., Kelekis D.A., et al. Endovascular stenting for the management of port-a-cath associated superior vena cava syndrome. Emerg Radiol. 2009; 16(2): 143–6. https://doi.org/10.1007/s10140-008-0714-5
  45. Kim D., Ryu D., Jung H. et al. Evaluation of complications of totally implantable central venous port system insertion. Exp Ther Med. 2019; 17(3): 2013–8. https://doi.org/10.3892/etm.2019.7185
  46. Saber W., Moua T., Williams E.C., et al. Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J Thromb Haemost. 2011; 9(2): 312–9. https://doi.org/10.1111/j.1538-7836.2010.04126.x
  47. Cherkashin M., Berezina N., Puchkov D. et al. Femoral Access for Central Venous Port System Implantation. Cureus. 2018; 10(3): e2327. https://doi.org/10.7759/cureus.2327
  48. Merrer J., De Jonghe B., Golliot F., et al. French Catheter Study Group in Intensive Care. Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial. JAMA. 2001; 286(6): 700–7. https://doi.org/10.1001/jama.286.6.700
  49. McGee D.C., Gould M.K. Preventing complications of central venous catheterization. N Engl J Med . 2003; 348(12): 1123–33. https://doi.org/10.1056/NEJMra011883
  50. Галстян Г.М., Спирин М.В., Дроков М.Ю., и др. Преимущества и недостатки порт-систем, установленных бедренным доступом, у гематологических больных с синдромом верхней полой вены. Гематология и трансфузиология. 2020; 65(4): 403–16. https://doi.org/10.35754/0234-5730-2020-65-4-403-416.
  51. Treiman G.S., Silberman H. Chronic venous access in patients with cancer. Selective use of the saphenous vein. Cancer. 1993; 72(3): 760–5. https://doi.org/10.1002/1097-0142(19930801)72:3<760::aid-cncr2820720320>3.0.co;2-j
  52. Kariya S., Nakatani M., Maruyama T., et al. Central venous access port placement by translumbar approach using angio-CT unit in patients with superior vena cava syndrome. Jpn J Radiol. 2018; 36(7): 450–5. https://doi.org/10.1007/s11604-018-0742-3
  53. Puel V., Caudry M., Le Métayer P., et al. Superior vena cava thrombosis related to catheter malposition in cancer chemotherapy given through implanted ports. Cancer. 1993; 72(7): 2248–52. https://doi.org/10.1002/1097-0142(19931001)72:7<2248::aid-cncr2820720731>3.0.co;2-u
  54. Trerotola S.O., Kuhn-Fulton J., Johnson M.S., et al. Tunneled infusion catheters: increased incidence of symptomatic venous thrombosis after subclavian versus internal jugular venous access. Radiology. 2000; 217(1): 89–93. https://doi.org/10.1148/radiology.217.1.r00oc2789
  55. Vidal E, Sharathkumar A, Glover J, Faustino EV. Central venous catheter-related thrombosis and thromboprophylaxis in children: a systematic review and meta-analysis. J ThrombHaemost. 2014; 12(7): 1096–109. https://doi.org/10.1111/jth.12598
  56. Niers T.M., Di Nisio M., Klerk C.P., et al. Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study. J Thromb Haemost. 2007; 5(9): 1878–82. https://doi.org/10.1111/j.1538-7836.2007.02660.x
  57. Geerts W. Central venous catheter-related thrombosis. Hematology Am Soc Hematol Educ Program. 2014 Dec 5; 2014(1): 306–11. https://doi.org/10.1182/asheducation-2014.1.306
  58. Sousa B., Furlanetto J., Hutka M., et al. ESMO Guidelines Committee. Central venous access in oncology: ESMO Clinical Practice Guidelines. Ann Oncol. 2015; 26(5): v152–68. https://doi.org/10.1093/annonc/mdv296
  59. Simon A., Graf N., Furtwängler R. Results of a multicentre survey evaluating clinical practice of port and Broviac management in paediatric oncology. Klin Padiatr. 2013 May; 225(3): 145–51. https://doi.org/10.1055/s-0033-1333762.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © , 2022

##common.cookie##